In the general US population, serum 25-hydroxyvitamin D levels are inversely associated with several cardiovascular risk factors, including hypertension, diabetes, obesity, and hyperlipidemia.1 Low levels of serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D [1,25(OH) 2 D 3 ] are associated with congestive heart failure and an increased rate of all-cause and cardiovascular mortality.
2-4Prospective studies have demonstrated an association between low serum 25-hydroxyvitamin D levels and increased risk of incident cardiovascular disease and myocardial infarction. 5,6 In patients with chronic kidney disease, where cardiovascular disease is the leading cause of death, therapy with activated vitamin D is associated with a reduction in mortality. 7,8 Vitamin D's cardiovascular effects may be mediated in part by regulation of the renin-angiotensin system (RAS).9,10 1,25(OH) 2 D 3 and its analogs inhibit renin expression in vivo 11 and an inverse correlation has been reported between levels of serum 1,25(OH) 2 D 3 and plasma renin activity in humans.12,13 A therapeutic effect of vitamin D in humans, however, has not been conclusively demonstrated. Pharmacological inhibition of the RAS with angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) is commonly